Body mass index associated with severity and mortality of patients with coronavirus disease 2019: A systematic review and meta-analysis

Chao Fang (✉ 6513067@zju.edu.cn)  
Zhejiang University School of Medicine Children's Hospital  
https://orcid.org/0000-0002-3903-9303

Zheng Zhou  
Zhejiang University School of Medicine Children's Hospital

Mingming Zhou  
Zhejiang University School of Medicine Children's Hospital

Jianping Li  
Zhejiang University School of Medicine Children's Hospital

Research

Keywords: Body mass index, COVID-19, Severity, Mortality, Systematic review, Meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-79456/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

As an important indicator to measure obesity or underweight, body mass index (BMI) can be used to assess the potential risk for various diseases. The present study systematically examined the relationship between BMI and severity and mortality of patients with coronavirus disease 2019 (COVID-19).

Methods

We systematically searched PubMed, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI) for studies published as of September 3, 2020 and extracted the relevant data of research endpoints in each study.

Results

This study included 16 studies with 6087 patients. This study observed a significant increase in BMI on admission in patients with severe COVID-19 compared with those with non-severe COVID-19 (Mean difference [MD] = 1.95, 95% confidence interval [CI], 1.52−2.37, \( I^2 = 33\% \), \( P < 0.00001 \)). A significant increase in BMI on admission was observed in patients who died from COVID-19 compared with (MD = 3.01, 95% CI: 1.83 to 4.19, \( I^2 = 0\% \), \( P < 0.00001 \)). In the intensive care unit (ICU) or geriatric ward, the study observed a significant decrease in BMI in the non-survivor group compared with the survivor group (MD = -1.61, 95% CI: -3.07 to -0.16, \( I^2 = 72\% \), \( P = 0.03 \)).

Conclusions

Higher BMI on admission is associated with severity and mortality of patients with COVID-19, but lower BMI is associated with mortality of patients with COVID-19 in the ICU or geriatric ward. Thus, we strongly recommend that clinicians should closely monitor the BMI of patients with COVID-19, especially those from the ICU or geriatric ward.

Introduction

In late December 2019, a group of patients with pneumonia of unknown cause was reported by several local health facilities in Wuhan, China(1). This pneumonia of unknown cause was later shown to be caused by a highly infectious novel coronavirus infection (2). According to research, the novel coronavirus is a single positive-stranded RNA virus from the Coronaviridae family and have enveloped virions that appear as round or oval, with a diameter of 60–140 nm, often polymorphous (3) (4). Subsequently, this novel coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(5). The WHO has named this infectious disease as coronavirus disease 2019 (COVID-19), which has spread worldwide and caused many deaths(6, 7).

The clinical features of COVID-19 mainly included fever, cough, sputum, dyspnea, myalgia, malaise, fatigue, diarrhea, etc(8–13). Although the mortality rate of COVID-19 is approximately 4%, COVID-19 has a higher rate of spread and become a global pandemic in a very short time compared with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (14). As a result, the death toll from COVID-19 is high in absolute terms. Comparing the clinical and epidemiological features between severe/non-survivors and non-severe/survivors, a large number of literature reports have found some risk factors for exacerbation prediction of patients with COVID-19, such as hypertension, diabetes, cerebrovascular disease, chronic obstructive pulmonary disease, etc (15–19). As a statistical index to estimate body fat, body mass index (BMI) seems to be related to exacerbation prediction of patients with COVID-
According to some recent and published studies, higher BMI (obesity) seems to be a risk for exacerbation prediction of patients with COVID-19 (21–23). However, some problems cannot be avoided, for example: (1) when race, sex, region, and age are different, BMI threshold for obesity is different. As a result, multiple data combinations cannot be measured with the same BMI threshold. (2) Is lower BMI associated with exacerbation prediction of patients with COVID-19 under special circumstances? To this end, we systematically and comprehensively evaluated the relationship between BMI and the severity and mortality of patients with COVID-19.

**Methods**

**Search strategy**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was used for this systematic review and meta-analysis and the PROSPERO registration ID is CRD42020205688 (24). We selected relevant studies published as of September 3, 2020, by searching PubMed, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI). Language restrictions were not applied. The following combined text was used in this systematic review and meta-analysis and MeSH terms: "Body Mass Index" and "COVID-19". The complete search used for PubMed was: (((((("COVID-19" [Supplementary Concept]) OR (2019 novel coronavirus disease)) OR (COVID19)) OR (COVID-19 pandemic)) OR (SARS-CoV-2 infection)) OR (COVID-19 virus disease)) OR (2019 novel coronavirus infection)) OR (2019-nCoV infection)) OR (coronavirus disease 2019)) OR (coronavirus disease-19)) OR (2019-nCoV disease)) OR (COVID-19 virus infection)) AND (((("Body Mass Index"[Mesh]) OR (Index, Body Mass)) OR (Quetelet Index)) OR (Index, Quetelet)) OR (Quetelet's Index)) OR (Quetelets Index))

**Selection criteria**

Inclusion criteria were (1) patients diagnosed with COVID-19; (2) continuous variable (BMI) expressed as mean ± SD/median and interquartile range (IQR); (3) comparison between patients with severe and non-severe COVID-19, or between COVID-19 survivors and non-survivors. Exclusion criteria were (1) basic researches, guidelines, case reports, review, editorials, or other unrelated topics; (2) those without continuous variable data for BMI; (3) studies with a sample size of < 10.

**Data extraction and quality assessment**

Two investigators independently extracted data from the included studies. Pairs of reviewers (Zheng Zhou; Mingming Zhou) independently extracted data from the included studies, and disagreements were resolved by a third reviewer (Chao Fang).

The following data were extracted from each selected study: details of authors, mean age, total sample size, continuous variable (BMI), and clinical condition (non-severe/severe; non-survivors/survivors). Because most of the included studies were retrospective cohort studies, the Newcastle–Ottawa scale was used for quality evaluation (25).

**Statistical analysis**

All analyses and plots were performed and made using the Review Manager software (RevMan5.4; Cochrane Collaboration). Statistical significance was determined for P < 0.05. By attaining the mean ± SD and sample size (n) of severe and non-severe groups (or survivor and non-survivor groups), the standardized mean differences were used as the summary statistic for continuous data. The mean was estimated by \((Q_a + M + Q_c)/3\), and the standard deviation was estimated by \((Q_c - Q_a)/1.35\), when the included studies did not provide the mean and standard deviation but provided median (M) and upper (Q_c) and lower quartiles (Q_a) instead (26).
The Q statistic was to estimate the heterogeneity in this study, and $P \leq 0.10$ was considered statistically significant for the Q-statistic test. \( \hat{I} \) statistic was used to quantify heterogeneity. When the value of \( \hat{I} \) is 0, heterogeneity is not observed, the heterogeneity increased with larger value of \( \hat{I} \). To obtain the expected heterogeneity, random-effects model was used in advance. Fixed-effects models are applied if the Q statistic $P > 0.10$.

**Results**

**Study selection**

We identified 553 citations, and 88 duplicate citations were removed.

After screening the title and abstract, 426 records were excluded, and 39 potentially relevant publications were retrieved for eligibility. After screening the full-text articles, 23 more records were excluded because of failure to extract valid continuous variables (BMI, expressed as mean ± SD) or no proper grouping. Ultimately, 16 studies published as of September 3, 2020, including 6087 patients, met our inclusion criteria (27–42). The outline of the search strategy is presented in Fig. 1.

**Study characteristics**

The baseline characteristics of each included study are summarized in Table 1. The 16 included research papers were mainly observational cohort studies and published/available online until September 3, 2020. Seven studies were from China, six were from the USA, and the remaining three were from Spain, Mexico, and Italy. Most of the studies were published in English, but two studies were published in Chinese. The number of patients with COVID-19 enrolled in each study ranged from 30 to 2215, and no study had a sample size < 10. The median or mean age of patients with COVID-19 approximately varied from 35 to 90 years. Ten studies were grouped by COVID-19 severe vs. non-severe, six studies were grouped by COVID-19 non-survivors vs. survivors. No obvious difference was found for the sex distribution of patients with COVID-19 for each study and not shown in Table 1.
Table 1
Baseline characteristics of each included study.

| Study                    | Year | Country | Language | Age (mean ± SD or median, range) | Groups                          | simple size | BMI, mean (SD)                  |
|--------------------------|------|---------|----------|----------------------------------|--------------------------------|-------------|-------------------------------|
| Auld, S. et al.          | 2020 | USA     | English  | 64.00 (54.00–73.00)              | Non-survivors vs survivors    | 181         | 29.00(4.44) 31.33(6.67)       |
| Alkhatib, A. L. et al.   | 2020 | USA     | English  | Severe: 62 ± 14.60; Non-Severe: 55.00 ± 14.70 | Severe vs non-severe          | 158         | 36.50(7.80) 31.90(8.50)       |
| Cai, Q. et al.           | 2020 | China   | English  | 47.00 (33.00–61.00)              | Severe vs non-severe          | 298         | 24.5(4.3) 22.90(3.41)         |
| Cai, S. H. et al.        | 2020 | China   | English  | BMI < 24: 35.41 ± 18.45; BMI ≥ 24: 44.00 ± 17.23 | Severe vs non-severe          | 96          | 24.89(3.17) 22.35(3.56)       |
| Chen, Q. et al.          | 2020 | China   | English  | 47.50 ± 14.60                   | Severe vs non-severe          | 145         | 24.94(2.88) 23.52(3.00)       |
| Gayam, V. et al.         | 2020 | USA     | English  | 67.00 (56.00–76.00)             | Non-survivors vs survivors    | 408         | 31.77(7.78) 28.97(6.37)       |
| Gupta, S. et al.         | 2020 | USA     | English  | 60.50 ± 14.50                   | Non-survivors vs survivors    | 2215        | 30.67(7.16) 31.23(7.11)       |
| Hundt, M. A. et al.      | 2020 | USA     | English  | 65.00 (1.00–103.00)             | Severe vs non-severe          | 1827        | 30.70(8.50) 29.20(7.30)       |
| Liu, M. et al.           | 2020 | China   | Chinese  | 35.00 ± 8.00                    | Severe vs non-severe          | 30          | 27.00(2.50) 22.00(1.30)       |
| Mani, V. R. et al.       | 2020 | USA     | English  | 64.72 (28.00–97.00)             | Severe vs non-severe          | 184         | 31.47(8.65) 28.45(7.02)       |
| Muñoz, Pet al.           | 2020 | Spain   | English  | 61.50(39.50–82.00)              | Non-survivors vs survivors    | 100         | 30.33(5.04) 27.60(4.52)       |
| Ortiz-Brizuela, E. et al.| 2020 | Mexico  | English  | 43.00 (11.00–92.00)             | Severe vs non-severe          | 140         | 30.47(5.06) 28.42(4.22)       |
| Recinella, G. et al.     | 2020 | Italy   | English  | Survivor: 80.50 (73.70–92.20)   | Non-survivor: 90 (82.00–95.00) | 37          | 22.77(1.48) 25.30(4.15)       |
| Study            | Year | Country | Language | Age (mean ± SD or median, range) | Groups                                | simple size | BMI, mean (SD)             |
|------------------|------|---------|----------|----------------------------------|---------------------------------------|-------------|---------------------------|
|                  |      |         |          |                                  | Severe vs non-severe                   |             | **Severe/non-survived** | **Non-severe/survived** |
| Xu, J.et al.     | 2020 | China   | Chinese  | 41.99 ± 15.42                    | Severe vs non-severe                   | 155         | 25.69(3.22)              | 23.75(3.17)              |
| Yu, T.et al.     | 2020 | China   | English  | Severe: 49.58 ± 22.16; Non-Severe: 38.37 ± 15.80 | Severe vs non-severe                   | 70          | 25.38(2.49)              | 22.95(3.61)              |
| Zhang, F.et al.  | 2020 | China   | English  | 14.00–45.00 (median unknown)     | Non-survivors vs survivors             | 43          | 27.79(5.18)              | 23.38(3.02)              |

**Quality assessment**

The quality assessment of the included studies, using the Newcastle–Ottawa scale, is shown in Table 2. The risk of bias assessment of these studies was based on three main categories of selection, comparability, and exposure. All eligible studies received five or more stars.
Table 2  
Newcastle–Ottawa quality assessment scale of cohort studies for included studies.

| Study ID        | Selection (max 4 stars) | Comparability (max 2 stars) | Exposure (max 3 stars) | Total stars |
|-----------------|-------------------------|----------------------------|------------------------|-------------|
|                 | (1) (2) (3) (4)         | (1) (2)                     | (3)                    |             |
| Auld, S.et al.  | 0 * 0 0               | *                          | *                      | 5           |
| Alkhatib, A. L.et al. | 0 * 0 0               | *                          | *                      | 5           |
| Cai, Q.et al.   | 0 * 0 0               | *                          | *                      | 5           |
| Cai, S. H.et al.| * * 0 0               | *                          | *                      | 6           |
| Chen, Q.et al.  | 0 * 0 0               | *                          | *                      | 5           |
| Gayam, V.et al. | * * 0 0               | *                          | *                      | 6           |
| Gupta, S.et al. | 0 * 0 0               | *                          | *                      | 5           |
| Hundt, M. A.et al. | 0 * 0 0               | *                          | *                      | 5           |
| Liu, M.et al.   | 0 * 0 0               | *                          | *                      | 5           |
| Mani, V. R.et al.| 0 * 0 0               | *                          | *                      | 5           |
| Muñoz, P.et al. | 0 * 0 0               | *                          | *                      | 5           |
| Ortiz-Brizuela, E.et al.| * * 0 0 | *                      | *                      | 6           |
| Recinella, G.et al. | 0 * 0 0               | **                        | *                      | 6           |
| Xu, J.et al.    | 0 * 0 0               | *                          | *                      | 5           |
| Yu, T.et al.    | 0 * 0 0               | *                          | *                      | 5           |
| Zhang, F.et al. | 0 * 0 0               | *                          | *                      | 5           |

**Selection**

1. Is the case definition adequate? (a) yes, with independent validation*, (b) yes, e.g. record linkage or based on self-reports, (c) no description.

2. Representativeness of the cases: (a) consecutive or obviously representative series of cases*, (b) potential for selection biases or not stated.

3. Selection of controls: (a) community controls*, (b) hospital controls, (c) no description.

4. Definition of controls: (a) no history of disease (end-point)*, (b) no description of source

**Comparability**

1. Comparability of cases and controls on basis of design or analysis: (a) study controls for ___ (most important factor)*, (b) study controls for any additional factor* (could be modified to indicate specific control for a second factor).

**Exposure**

1. Ascertainment of exposure: (a) secure record (e.g. surgical records)*, (b) structured interview where blind to case/control status*, (c) interview not blinded to case/control status, (d) written self-report or medical record only, (e) no description.

2. Same method of ascertainment for cases and controls: (a) yes*, (b) no.
Publication bias

Ten studies were included in the analysis regarding the association between BMI and severity of patients with COVID-19. The remaining six studies were used to analyze the correlation of BMI and the mortality of patients with COVID-19. Due to the limited power among studies, and the outcome was no more than 10 for the funnel plot, publication bias was not calculated(43).

Correlation of BMI and severity of patients with COVID-19

The severe and non-severe groups included 941 and 2162 patients with COVID-19, respectively. Based on the ten included studies, a significant increase in BMI on admission was observed in severe patients with COVID-19 compared with non-severe patients with COVID-19 for the fixed-effects model (Mean difference [MD] = 1.95, 95% confidence interval [CI], 1.52 − 2.37, $I^2 = 33\%$, $P < 0.00001$). The result of the correlation of BMI and severity of patients with COVID-19 is shown in Fig. 2.

Correlation of BMI and mortality of patients with COVID-19

The non-survivor and survivor groups included 1014 and 1970 patients with COVID-19, respectively. Based on the six included studies, no obvious change in BMI was found in COVID-19 non-survivors compared with survivors for the random-effects model (MD = 0.55, 95% CI: -1.33 to 2.43, $I^2 = 88\%$, $P = 0.57$). The result is shown in Fig. 3A. For the subgroup analysis, a significant increase in BMI on admission was observed in COVID-19 non-survivors compared with survivors for the fixed-effects model (MD = 3.01, 95% CI: 1.83 to 4.19, $I^2 = 0\%$, $P< 0.00001$). The result is shown in Fig. 3B. In the intensive care unit (ICU) or geriatric ward, the BMI significantly decreased in COVID-19 non-survivors compared with survivors for the random-effects model in the subgroup analysis (MD = -1.61, 95% CI: -3.07 to -0.16, $I^2 = 72\%$, $P = 0.03$). The result is shown in Fig. 3C.

Discussion

Higher BMI tends to indicate overweight or obesity, which is associated with increased morbidity and mortality from various diseases(44, 45). Similarly, higher BMI is associated with increased risk of acquiring infections with worse outcomes(46). With more in depth research, obesity seems to be a risk factor for exacerbation prediction of patients with COVID-19. In the systematic review or meta-analysis published to date, BMI is usually analyzed as a dichotomous variable. Multiple data sets from different races, sexes, regions, and ages were measured using the same BMI threshold, which may not be appropriate. Therefore, this study summarized currently available research regarding the correlation between BMI and the severity and mortality of patients with COVID-19 in the form of continuous variables.

In this study, BMI on admission significantly increased in patients with severe COVID-19 compared with non-severe patients. This suggests that patients admitted with higher BMI are more likely to develop severe COVID-19 infection. However, we did not observe a significant change in BMI in COVID-19 non-survivors compared with survivors. The statistical results showed very high heterogeneity, up to 88%. Further analysis of the six included studies were showed that the patients of the three studies were mainly from the ICU or geriatric ward and tend to have a long history of

| Study ID | Selection (max 4 stars) | Comparability (max 2 stars) | Exposure (max 3 stars) | Total stars |
|----------|-------------------------|-----------------------------|------------------------|-------------|
|          | (1)                     | (2)                         | (3)                    |             |
|          | (4)                     | (1)                         | (2)                    |             |
|          | (3)                     |                             |                        |             |

(3) Non-response rate: (a) same rate for both groups*, (b) non-respondents described, (c) rate different and no designation.
hospitalization. Thus, a subgroup analysis was performed. A significant increase in BMI on admission was observed in COVID-19 non-survivors compared with survivors. This suggests that the risk of mortality of patients with COVID-19 with higher BMI on admission increases. Nevertheless, a significant decrease in BMI was observed in the non-survivor group compared with the survivor group in the ICU or geriatric ward. It is may be related to a worsened nutritional status of patients with COVID-19 from the ICU or geriatric ward. A similar phenomenon was also observed by other previous studies; for example, patients with BMI < 20 had greater 60-day mortality in the ICU setting (47); lower BMI was associated with a higher risk of death for patients with sepsis (48); patients who are underweight have a higher mortality rate in the pediatric ICU (49). Hence, patients with COVID-19 from the ICU or geriatric ward may need to maintain BMI within the normal range.

Finally, this study has several limitations: (1) Due to the lack of prospective study or randomized controlled trial, studies included in our analysis are mainly retrospective cohort studies. (2) Although we observed a significant decrease in BMI in the non-survivor group compared with the survivor group in the ICU or geriatric ward, more research is needed for further analysis. (3) Most studies included in this study were conducted in China or USA, and studies from other countries or regions need to be included in future studies.

Conclusion

In summary, higher BMI on admission is associated with severity and mortality of patients with COVID-19, but lower BMI is associated with mortality of patients with COVID-19 in the ICU or geriatric ward. BMI should be used properly based on the different situation of patients with COVID-19 during treatment.

Declarations

Ethics approval and consent to participate:

Not applicable.

Consent for publication:

Not applicable.

Availability of data and materials:

Data sharing is not applicable to this article.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions:

CF takes responsibility for the conception and design of the study and drafting the article. ZZ and MZ contributed to acquisition and analysis and interpretation of data. JL contributed to manuscript review and editing. All authors read and
approved the final manuscript.

Acknowledgements:
Not applicable

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
2. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020;395(10226):809-15.
3. Asif M, Saleem M, Saadullah M, Yaseen HS, Al Zarzour R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 2020.
4. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020;71(15):706-12.
5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. The Lancet Infectious Diseases. 2020.
6. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet Infectious Diseases. 2020;20(6):689-96.
7. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901.
8. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.
10. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020;8(5):475-81.
11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62.
12. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):748-55.
13. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769-77.
14. Pormohammad A, Ghorbani S, Khatami A, Farzi R, Baradaran B, Turner DL, et al. Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis. Rev Med Virol. 2020;30(4):e2112.
15. Dalan R, Ang LW, Tan WYT, Fong SW, Tay WC, Chan YH, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2020.
16. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403.
17. Cristelo C, Azevedo C, Marques JM, Nunes R, Sarmento B. SARS-CoV-2 and diabetes: New challenges for the disease. Diabetes Res Clin Pract. 2020;164:108228.
18. Siepmann T, Sedghi A, Barlinn J, de With K, Mirow L, Wolz M, et al. Association of history of cerebrovascular disease with severity of COVID-19. J Neurol. 2020.
19. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020.
20. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
21. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. Journal of medical virology. 2020.
22. Hussain A, Mahawar K, Xia Z, Yang W, S EL-H. Obesity and mortality of COVID-19. Meta-analysis. Obesity Research and Clinical Practice. 2020.
23. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020;142(1):4-6.
24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
25. G W. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa. 2014.
26. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
27. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network. Hepatology (Baltimore, Md). 2020.
28. Xu J, Zhao F, Han M, Ma L, Zhang T. Analysis of the clinical characteristics and early warning model construction of severe/critical coronavirus disease 2019 patients. Zhonghua Wei Bing Ji Jiu Yi Xue. 2020;32(4):401-6.
29. Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clinical Therapeutics. 2020.
30. Cai SH, Liao W, Chen SW, Liu LL, Liu SY, Zheng ZD. Association between obesity and clinical prognosis in patients infected with SARS-CoV-2. Infectious Diseases of Poverty. 2020;9(1).
31. Mani VR, Kalabin A, Valdivieso SC, Murray-Ramcharan M, Donaldson B. At the epicenter of the American Coronavirus outbreak - New York inner city hospital COVID-19 experience and current data: a retrospective analysis. J Med Internet Res. 2020.
32. Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Díaz-Mejía BA, et al. Clinical and Epidemiological Characteristics of Patients Diagnosed with COVID-19 in a Tertiary Care Center in Mexico City: A Prospective Cohort Study. Rev Invest Clin. 2020;72(3):165-77.
33. Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia. Zhonghua Jie He Hu Xi Za Zhi. 2020;43(3):209-14.
34. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020:1-9.
35. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy: European Journal of Allergy and Clinical Immunology. 2020;75(7):1742-52.
36. Gayam V, Chobufo MD, Merghani MA, Lamichanne S, Garlapati PR, Adler MK. Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York. Journal of medical virology. 2020.

37. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA internal medicine. 2020.

38. Muñoz P, Galar A, Catalán P, Valerio M, Aldamiz-Echevarría T, Cólliga C, et al. The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2020.

39. Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT, et al. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv. 2020.

40. Zhang F, Xiong Y, Wei Y, Hu Y, Wang F, Li G, et al. Obesity predisposes to the risk of higher mortality in young COVID-19 patients. Journal of Medical Virology. 2020.

41. Recinella G, Marasco G, Di Battista A, Bianchi G, Zoli M. Prognostic role of nutritional status in elderly patients hospitalized for COVID-19. Medical Hypotheses. 2020;144.

42. Alkhatib AL, Kreniske J, Zifodya JS, Fonseca V, Tambah M, Khatib J, et al. BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans. Obesity (Silver Spring). 2020.

43. Roig M. Ethical writing should be taught. BMJ. 2006;333(7568):596-7.

44. Adams B, Jacocks L, Guo H. Higher BMI is linked to an increased risk of heart attacks in European adults: a Mendelian randomisation study. BMC Cardiovasc Disord. 2020;20(1):258.

45. Abston E, Comellas A, Reed RM, Kim V, Wise RA, Brower R, et al. Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25-75/FVC) in COPD. BMJ Open Respir Res. 2017;4(1):e000231.

46. Atamna A, Elia E, Gilady E, Gitter-Azulay L, Bishara J. How obesity impacts outcomes of infectious diseases. European Journal of Clinical Microbiology & Infectious Diseases. 2016;36(3):585-91.

47. Compher C, Chittams J, Sammarco T, Higashibeppu N, Higashiguchi T, Heyland DK. Greater Nutrient Intake Is Associated With Lower Mortality in Western and Eastern Critically Ill Patients With Low BMI: A Multicenter, Multinational Observational Study. Journal of Parenteral and Enteral Nutrition. 2019;43(1):63-9.

48. Zhou Q, Wang M, Li S, Zhang J, Ma Q, Ding Y, et al. Impact of body mass index on survival of medical patients with sepsis: a prospective cohort study in a university hospital in China. BMJ Open. 2018;8(9):e021979.

49. Ayalon I, Woo JG, Basu RK, Kaddourah A, Goldstein SL, Kaplan JM. Weight as a Risk Factor for Mortality in Critically Ill Patients. Pediatrics. 2020;146(2).

Figures
Figure 1
Flow chart of included studies.

| Study or Subgroup | Experimental | Control | Mean Difference | Mean Difference |
|-------------------|--------------|---------|-----------------|-----------------|
|                   | Mean  | SD    | Total | Mean  | SD    | Total | Weight | IV, Fixed | 95% CI | IV, Fixed | 95% CI |
| Alkhathib, A. L.   | 36.5  | 7.8   | 46    | 31.9  | 8.5   | 112   | 2.4%   | 4.60      | [1.85, 7.35] |  |  |
| Cai, Q.            | 24.5  | 4.3   | 58    | 22.9  | 3.41  | 240   | 12.9%  | 1.60      | [0.41, 2.79] |  |  |
| Cai, S. H.         | 24.89 | 3.17  | 30    | 22.35 | 3.56  | 66    | 9.0%   | 2.54      | [1.12, 3.96] |  |  |
| Chen, Q.           | 24.94 | 2.88  | 43    | 23.52 | 3     | 102   | 16.9%  | 1.42      | [0.38, 2.46] |  |  |
| Hundt, M. A.      | 30.7  | 8.5   | 652   | 29.2  | 7.3   | 1175  | 30.4%  | 1.50      | [0.73, 2.27] |  |  |
| Liu, M.            | 27    | 2.5   | 4     | 22    | 1.3   | 26    | 2.9%   | 5.00      | [2.50, 7.50] |  |  |
| Mani, V. R.        | 31.47 | 8.645 | 30    | 28.45 | 7.017 | 154   | 1.7%   | 3.02      | [0.27, 6.31] |  |  |
| Ortiz-Brizuela, E. | 30.47 | 5.06  | 29    | 28.42 | 4.22  | 111   | 4.5%   | 2.05      | [0.05, 4.05] |  |  |
| Xu, J.             | 25.69 | 3.22  | 30    | 23.75 | 3.17  | 125   | 11.1%  | 1.94      | [0.66, 3.22] |  |  |
| Yu, T.             | 25.38 | 2.49  | 19    | 22.95 | 3.61  | 51    | 8.2%   | 2.43      | [0.93, 3.93] |  |  |

Total (95% CI) 941 2162 100.0% 1.95 [1.52, 2.37]

Heterogeneity: $\chi^2 = 13.39$, df = 9 ($P = 0.15$); $I^2 = 33$
Test for overall effect: $Z = 8.93$ ($P < 0.00001$)

Figure 2
Forest plot: correlation of BMI and severity of patients with COVID-19.
Figure 3

Forest plot: the correlation of BMI and the mortality of COVID-19 patients

A: Forest plot: correlation of BMI and mortality of patients with COVID-19 based on the six included studies.
B: Forest plot: BMI on admission in COVID-19 non-survivors compared with survivors in the subgroup analysis.
C: Forest plot: the BMI of the non-survivor group compared with the survivor group in the ICU or geriatric ward in the subgroup analysis.